Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), Castle Biosciences (CSTL) and Viridian Therapeutics (VRDN)

Tipranks - Tipranks - Wed Nov 5, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Castle Biosciences (CSTL – Research Report) and Viridian Therapeutics (VRDN – Research Report).

Meet Your ETF AI Analyst

Sarepta Therapeutics (SRPT)

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Sarepta Therapeutics today and set a price target of $20.00. The company’s shares closed last Tuesday at $15.51.

According to TipRanks.com, Ulz is a 4-star analyst with an average return of 4.7% and a 44.6% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $24.40 average price target, which is a -0.2% downside from current levels. In a report issued on October 22, RBC Capital also maintained a Hold rating on the stock with a $16.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Castle Biosciences (CSTL)

In a report released today, Thomas Flaten from Lake Street reiterated a Buy rating on Castle Biosciences, with a price target of $35.00. The company’s shares closed last Tuesday at $26.65.

According to TipRanks.com, Flaten is a 5-star analyst with an average return of 18.0% and a 54.2% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Rapid Micro Biosystems, and Aquestive Therapeutics. ;'>

Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $32.91, which is a 26.6% upside from current levels. In a report issued on October 27, Canaccord Genuity also maintained a Buy rating on the stock with a $23.56 price target.

Viridian Therapeutics (VRDN)

In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on Viridian Therapeutics. The company’s shares closed last Tuesday at $22.85.

According to TipRanks.com, Thome is a 5-star analyst with an average return of 20.6% and a 56.0% success rate. Thome covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arrowhead Pharmaceuticals, and Entrada Therapeutics Inc. ;'>

Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $38.08, representing a 64.5% upside. In a report issued on October 20, LifeSci Capital also maintained a Buy rating on the stock with a $46.00 price target.

Read More on SRPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).